胸腺肽α1对乙型肝炎肝硬化失代偿期患者淋巴细胞亚群的影响

仝静; 孙长宇; 杨黎冰; 梁亚林; 康艳楠

doi:10.3969/j.issn.1001-5256.2017.11.016

胸腺肽α1对乙型肝炎肝硬化失代偿期患者淋巴细胞亚群的影响

DOI: 10.3969/j.issn.1001-5256.2017.11.016

郑州大学第一附属医院感染科

基金项目:

河南省医学科技攻关计划项目(152102310045)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 2150
- HTML全文浏览量: 39
- PDF下载量: 425
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-17
- 出版日期: 2017-11-20

Effect of thymosin α1 on lymphocyte subsets in patients with decompensated hepatitis B cirrhosis

Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University

Research funding:

摘要

摘要: 目的观察乙型肝炎肝硬化失代偿期患者应用胸腺肽α1后外周血淋巴细胞亚群的变化,分析胸腺肽α1对患者免疫功能的影响。方法选取2015年10月-2016年12月郑州大学第一附属医院收治的乙型肝炎肝硬化失代偿期患者106例,随机分为对照组和治疗组各53例,另选同期20例体检者作为健康组。对照组给予内科综合治疗,治疗组在综合治疗的基础上加用胸腺肽α1,分别于治疗前、治疗12周后使用流式细胞仪器检测患者外周血CD3+、CD4+、CD8+细胞数、CD4+/CD8+比值、CD19百分比、NK细胞百分比。观察临床症状和并发症,以及不良反应发生情况。计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验;两组间比较采用成组t检验或配对t检验。计数资料的组间比较采用χ2检验。结果治疗前,与健康组相比,治疗组和对照组患者外周血CD3+、CD4+、CD8+细胞数、CD4+/CD8
- 肝硬化 /
- 肝炎,乙型 /
- 淋巴细胞亚群 /
- 胸腺素
Abstract: Objective To investigate the change in peripheral blood lymphocyte subsets after the application of thymosin α1 in patients with decompensated hepatitis B cirrhosis, as well as the effect of thymosin α1 on immune function.Methods A total of 106 patients with decompensated hepatitis B cirrhosis who were admitted to The First Affiliated Hospital of Zhengzhou University from October 2015 to December 2016 were enrolled and randomly divided into control group and treatment group, with 53 patients in each group, and 20 healthy subjects who underwent physical examination were enrolled as healthy group.The patients in the control group were given comprehensive medical treatment, and those in the treatment group were given thymosin α1 in addition to the comprehensive medical treatment.Flow cytometry was used to measure peripheral blood CD3+, CD4+, and CD8+cells, CD4+/CD8+ratio, and percentages of CD19 cells and natural killer (NK) cells before treatment and after 12 weeks of treatment.Clinical symptoms, complications, and adverse events were observed.An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between any two groups;the independent-samples t test or paired t-test was used for comparison between two groups.The chi-square test was used for comparison of categorical data between groups.Results Before treatment, the treatment group and the control group had significantly lower numbers of peripheral blood CD3+, CD4+, and CD8+cells, CD4+/CD8+ratio, and percentages of CD19 cells and NK cells than the healthy group (all P<0.05) .After 12 weeks of treatment, the treatment group showed significant increases in the numbers of CD3+and CD4+cells and CD4+/CD8+ratio (t=7.647, 7.851, and 4.384, all P<0.001) ;compared with the control group, the treatment group had significantly increased numbers of CD3+, CD4+, and CD8+cells (t=5.051, 5.379, and 2.066, all P<0.05) and slightly increaseed CD4+/CD8+ratio and percentages of CD19 cells and NK cells (all P>0.05) .The adverse events during treatment included dizziness and headache, and there was no significant difference in the incidence rate of adverse events between the control group and the treatment group (χ2=1.039, P=0.308) .No patient experienced serious adverse events.Conclusion In patients with decompensated hepatitis B cirrhosis, thymosin α1 can significantly improve the imbalance of lymphocyte subsets and enhance their immune function.
- liver cirrhosis /
- hepatitis B /
- lymphocyte subsets /
- thymosin

HTML全文

参考文献(11)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]WANG Y, GAO Q, ZHAN YH.Changes of lymphocyte subsets in liver cirrhosis patients after hepatitis B[J].Chin J Gastroenterol Hepatol, 2015, (4) :452-454. (in Chinese) 王昀, 郜茜, 绽永华.乙型肝炎后肝硬化患者淋巴细胞亚群的变化[J].胃肠病学和肝病学杂志, 2015, (4) :452-454.

[3] DUAN HC, YU XH.Association of Child-Pugh classification with T lymphocyte subsets and NK cell changes in patients with hepatitis B cirrhosis[C].Proceedings of the Seventh National Conference on difficult and severe liver diseases.Beijing:[Publisher unknown], 2013. (in Chinese) 段惠春, 于晓辉.乙型肝炎肝硬化Child-Pugh分级与T淋巴细胞亚群和NK细胞变化的联系[C].第7届全国疑难及重症肝病大会论文集.北京:[出版者不详], 2013.

[4]LI ZJ, LI JS, ZHANG JP, et al.Clinical analysis of thymosin alpha combined with entecavir in the treatment of chronic hepatitis B[J].Chin J Dig, 2015, 35 (2) :127-129. (in Chinese) 李珍杰, 李建生, 张金平, 等.胸腺肽α联合恩替卡韦治疗慢性乙型肝炎的临床分析[J].中华消化杂志, 2015, 35 (2) :127-129.

[5]QIAO R, JIANG FJ, ZHANG Y.Clinical observation of Thymosinα1 on the influence of immune function of lymphocyte in elderly tumor patients[J].Chin J Med Offic, 2015, 43 (7) :707-709. (in Chinese) 乔锐, 姜凤久, 张岩.胸腺肽α1对高龄肿瘤患者淋巴细胞免疫功能的影响[J].临床军医杂志, 2015, 43 (7) :707-709.

[6]CHEN Y, FANG JK, CHEN XZ, et al.Effects of the Treg/Th17cell balance and their associated cytokines in patients with hepatitis B infection[J].Exp Ther Med, 2015, 9 (2) :573-578.

[7]XY DM, DI XZ.Mechanism and research progress of thymosin alpha 1[J].Med J Chin People's Health, 2014, 26 (2) :79-82. (in Chinese) 许冬梅, 邸秀珍.胸腺肽α1的作用机制及研究进展[J].中国民康医学, 2014, 26 (2) :79-82.

[8]ZHAGN HQ, LIU H, ZHOU T, et al.Clinical effect of adefovir dipivoxil combined with thymosinα1 in thd treatment of paitents with HBe Ag positive and no response to lamivudine[J].Int J Virol, 2016, 23 (2) :124-126. (in Chinese) 张华强, 刘海, 周涛, 等.阿德福韦酯联合胸腺肽α1治疗拉米夫定无应答的HBe Ag阳性慢性乙肝的疗效观察[J].国际病毒学杂志, 2016, 23 (2) :124-126.

[9]ZHANG P, HUANG QL, HUA ZC.Research progress of thymosin alpha 1[J].J Southeast Univ:Med Sci Edi, 2013, 32 (3) :344-350. (in Chinese) 张鹏, 黄启来, 华子春.胸腺肽α1的研究进展[J].东南大学学报:医学版, 2013, 32 (3) :344-350.

[10]WANG X, LI W, NIU C, et al.Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study[J].Inflammation, 2011, 34 (3) :198-202.

[11]DANIELLI R, FONSATTI E, CALABRO L, et al.Ann thymosinα1 in melanoma:from the clinical trial setting to the daily practice and beyond[J].Ann N Y Acad Sci, 2012, 1270:8-12.

施引文献

资源附件(0)

访问统计